Work

Exposure-response relationship for ramucirumab (RAM) from the randomized, double-blind, phase III REVEL trial (docetaxel [DOC] vs DOC plus RAM) in second-line treatment of metastatic non-small cell lung cancer (NSCLC).

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.8053

Authors: Egbert F. Smit, Maurice Perol, Martin Reck, Federico Cappuzzo, Paolo Bidoli, Roger B. Cohen, Ling Gao, C. Steven Ernest, Pablo Lee, Annamaria Zimmermann, David Ferry, Joseph Treat, Allen S. Melemed, Edward B. Garon

Institutions: Cancer Center Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, Centre Léon Bérard, German Center for Lung Research, LungenClinic Grosshansdorf, Ospedale di Livorno, Azienda Ospedaliera San Gerardo, University of Pennsylvania, Eli Lilly (United States), University of California, Los Angeles

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2603244353

Cites:

Cited by: 7

Related to: 10